Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Adrenocortical carcinoma, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to Adrenocortical carcinoma itself. Grouped by the type that holds them; each list opens that type's own page.
No targeted therapy despite defined genomic subgroups.
Mitotane toxicity and narrow therapeutic window.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Hormone excess drives morbidity and immunosuppression (cortisol blunts immunotherapy).
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Rarity: FIRM-ACT took 8 years and 40 centres for 300 patients.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 52 changes by month →When this page itself was last checked or edited.
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 1.0 year later, when the FDA's table was read.
Confirmed: the accelerated approval of 2021 converted to traditional approval 3.9 years after it was granted.
Confirmed: the accelerated approval of 2018 converted to traditional approval 5.2 years after it was granted.
Confirmed: the accelerated approval of 2023 converted to traditional approval 0.7 years after it was granted.
Confirmed: the accelerated approval of 2018 converted to traditional approval 4.8 years after it was granted.